Resources for Food and Drug Administration (FDA)

Adolor Under the FDA's Spotlight

www.fool.com

Drugmaker Adolor got a bit of surprising good news from the FDA on Friday, only a few weeks ahead of an upcoming FDA decision on whether to approve the company's lead drug.

The good news came in the form of a briefing document that the FDA released. In the document, which was released prior to the upcoming advisory panel discussion on Adolor's potential post-operative ileus (POI) treatment, Entereg, the agency gave what appeared to be a relatively positive review.

POI is a condition best described as constipation that occurs following abdominal surgery. For patients who have just had major surgical work on their bowels, it can be a serious and painful side effect and can prolong post-surgery hospital stays.

View the Resource

Share or bookmarklet this web page at: